3,4-Dihydro-1,4-benzodiazepin-5-one;1,2,3,4-tetrahydro-1,4-benzodiazepin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3,4-Dihydro-1,4-benzodiazepin-5-one;1,2,3,4-tetrahydro-1,4-benzodiazepin-5-one
• 英文别名: 3,4-dihydro-1,4-benzodiazepin-5-one;1,2,3,4-tetrahydro-1,4-benzodiazepin-5-one
• 化学式: C18H18N4O2
• 分子量: 322.4
• InChiKey: CXRCCKCYPGLGFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.97
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  82.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Cyclodextrin and antibody-drug conjugate formulations
  申请人：SEATTLE GENETICS, INC.

  公开号：US10391181B2

  公开（公告）日：2019-08-27

  Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.

  所公开的制剂包括液体制剂和冻干制剂，其中包含苯并二氮杂卓抗体-药物共轭物（ADC）和环糊精。还公开了纯化包含苯二氮卓抗体-药物共轭物和加工药物相关杂质的混合物的方法。
• ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCS
  申请人：Seattle Genetics, Inc.

  公开号：EP2968494B1

  公开（公告）日：2018-11-14
• ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCs
  申请人：Seattle Genetics, Inc.

  公开号：EP2968494A1

  公开（公告）日：2016-01-20
• CYCLODEXTRIN AND ANTIBODY-DRUG CONJUGATE FORMULATIONS
  申请人：SEATTLE GENETICS, INC.

  公开号：US20170232112A1

  公开（公告）日：2017-08-17

  Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
• US9987374B2
  申请人：——

  公开号：US9987374B2

  公开（公告）日：2018-06-05